NCT01023737 2023-02-13
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
Clinical Trials
10 trialsNCT00128102 2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00121277 2015-07-23
Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
University Health Network, Toronto
Phase 1 Completed
NCT00227513 2014-02-24
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00324480 2014-02-24
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00243100 2013-12-16
Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00331955 2013-07-02
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00287937 2013-02-07
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01353482 2012-03-22
MESO-02
University College, London
Phase 1/2 Withdrawn
NCT00801151 2010-05-20
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
Institut Claudius Regaud
Phase 1 Terminated